Sage Therapeutics saw the highest growth of 1.7% in patent filings and 1.12% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.34% and grants by 0.56%. GlobalData’s DataBook provides a comprehensive analysis of Sage Therapeutics‘s patent filings and grants. Buy the databook here.
Sage Therapeutics has been focused on protecting inventions in United States(US) with ten publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 24% filings and 25% grants. The Australia(AU), United States(US), China(CN), and European Patent Office(EPO) patent Office are among the top ten patent offices where Sage Therapeutics is filings its patents. Among the top granted patent authorities, Sage Therapeutics has 25% of its grants in United States(US), 20% in Spain(ES) and 10% in Australia(AU).
Roche and Johnson & Johnson could be the strongest competitors for Sage Therapeutics
Patents related to addiction and rare diseases lead Sage Therapeutics's portfolio
Sage Therapeutics has the highest number of patents in addiction followed by, rare diseases and climate change. For addiction, nearly 67% of patents were filed and 70% of patents were granted in Q2 2024.
Schizophrenia related patents lead Sage Therapeutics portfolio followed by traumatic brain injury, and anesthetic effect
Sage Therapeutics has highest number of patents in schizophrenia followed by traumatic brain injury, anesthetic effect, tinnitus, and pain. For schizophrenia, nearly 5% of patents were filed and 7% of patents were granted in Q2 2024.
For comprehensive analysis of Sage Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.